Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Key Highlights
- ➤CMND completes recruitment for first AUD cohort in Phase I/IIa trial
- ➤Part B tests 80 mg and 160 mg single doses in six-patient cohorts
- ➤CMND-100 evaluation advances from healthy volunteers to AUD patients
- ➤Trial assesses safety, tolerability, pharmacokinetics, and early efficacy signals
Expert Statements
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine
“Completing recruitment for the first portion of Part B marks a significant advancement for our CMND‑100 clinical program, as we transition from healthy volunteers to the very patient population we aim to impact”
Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder
Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD).
Get started
Create a free account to read the full story.